MX2020003546A - Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. - Google Patents
Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.Info
- Publication number
- MX2020003546A MX2020003546A MX2020003546A MX2020003546A MX2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- pharmaceutical formulation
- extended release
- release pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona una formulación oral de liberación prolongada para el tratamiento de la depresión resistente al tratamiento, la ansiedad resistente al tratamiento y la fobia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/728,695 US10441544B2 (en) | 2017-10-10 | 2017-10-10 | Extended release pharmaceutical formulation |
US201862695966P | 2018-07-10 | 2018-07-10 | |
PCT/IB2018/057851 WO2019073408A1 (en) | 2017-10-10 | 2018-10-10 | PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003546A true MX2020003546A (es) | 2020-08-03 |
Family
ID=66101315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003546A MX2020003546A (es) | 2017-10-10 | 2018-10-10 | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220347104A1 (es) |
EP (1) | EP3694832A4 (es) |
JP (1) | JP7364558B2 (es) |
CN (1) | CN111630026A (es) |
AU (1) | AU2018348359C1 (es) |
CA (1) | CA3077645A1 (es) |
MX (1) | MX2020003546A (es) |
WO (1) | WO2019073408A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
WO2020194087A2 (en) * | 2019-03-25 | 2020-10-01 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
US20210052517A1 (en) * | 2017-10-10 | 2021-02-25 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
US10869838B2 (en) * | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
CA3103440A1 (en) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
JP2022504036A (ja) | 2018-10-05 | 2022-01-13 | クレキシオ バイオサイエンシーズ エルティーディー. | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
CA3152593A1 (en) * | 2019-12-20 | 2021-06-24 | Tong-Ho Lin | Long-acting injectable formulations of ketamine pamoate salts |
WO2021137148A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
WO2021137147A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
CA2751627A1 (en) * | 2009-02-06 | 2010-08-12 | Egalet Ltd. | Pharmaceutical compositions resistant to abuse |
CN107412173A (zh) * | 2010-12-23 | 2017-12-01 | 普渡制药公司 | 抗篡改固体口服剂型 |
EP3804811A1 (en) * | 2013-05-13 | 2021-04-14 | Icahn School of Medicine at Mount Sinai | Treatment of mood and anxiety disorders |
CA2922507C (en) * | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
SI3215147T1 (sl) * | 2014-11-04 | 2024-05-31 | Acadia Pharmaceuticals Inc. | Nevroatenuacijske spojine norketamina in postopki |
US11471415B2 (en) * | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
-
2018
- 2018-10-10 EP EP18866768.7A patent/EP3694832A4/en active Pending
- 2018-10-10 CN CN201880074776.4A patent/CN111630026A/zh active Pending
- 2018-10-10 JP JP2020520241A patent/JP7364558B2/ja active Active
- 2018-10-10 MX MX2020003546A patent/MX2020003546A/es unknown
- 2018-10-10 AU AU2018348359A patent/AU2018348359C1/en active Active
- 2018-10-10 WO PCT/IB2018/057851 patent/WO2019073408A1/en unknown
- 2018-10-10 CA CA3077645A patent/CA3077645A1/en active Pending
-
2022
- 2022-06-28 US US17/851,590 patent/US20220347104A1/en active Pending
- 2022-06-28 US US17/851,451 patent/US20220354798A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220354798A1 (en) | 2022-11-10 |
WO2019073408A1 (en) | 2019-04-18 |
AU2018348359A1 (en) | 2020-04-23 |
EP3694832A4 (en) | 2021-07-14 |
AU2018348359B2 (en) | 2023-07-13 |
AU2018348359C1 (en) | 2023-10-12 |
JP7364558B2 (ja) | 2023-10-18 |
EP3694832A1 (en) | 2020-08-19 |
JP2020536901A (ja) | 2020-12-17 |
AU2018348359A8 (en) | 2020-04-30 |
CA3077645A1 (en) | 2019-04-18 |
US20220347104A1 (en) | 2022-11-03 |
CN111630026A (zh) | 2020-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003546A (es) | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
BR112019007806A2 (pt) | composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal | |
CL2018002359A1 (es) | Métodos para usar agonistas de fxr | |
ECSP19078196A (es) | Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
CL2017000824A1 (es) | Moduladores de regulador de conducta de transmembranas de fibrosis cística | |
ECSDI18019182S (es) | Dispositivo intranasal para suministro de fármacos | |
CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
CL2016000698A1 (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
CL2016002495A1 (es) | Derivados de piridina macrocíclicos . | |
CY1122024T1 (el) | Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
BR112018071370A2 (pt) | composições farmacêuticas orais de mesalazina | |
UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2017000151A1 (es) | Derivados de piridona | |
CL2019001038A1 (es) | Composición para el cuidado bucal. | |
CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas |